Skip to main content
Clinical Trials/NCT01231191
NCT01231191
Withdrawn
Phase 4

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Relationship Between Intraoperative Intravenous Acetaminophen and Postoperative Opioid Avoidance for Ambulatory Surgical Procedures

University of California, San Diego1 site in 1 countryNovember 1, 2010

Overview

Phase
Phase 4
Intervention
Intravenous acetaminophen
Conditions
Postoperative Pain
Sponsor
University of California, San Diego
Locations
1
Primary Endpoint
The primary endpoint is the difference in proportions of patients from each treatment group who avoid using any opioids following anesthesia emergence until recovery room discharge.
Status
Withdrawn
Last Updated
14 years ago

Overview

Brief Summary

This is a research study to determine if giving acetaminophen intravenously in hte operating room will decrease the number of patients who require additional pain medicine, such as morphine, after surgery in the recovery room.

Detailed Description

Primary Specific Aim: To determine if adding an intraoperative dose of intravenous acetaminphen to usual and customary analgesics during ambulatory surgery impacts the proportion of patients remaining opioid-free in the post-anesthesia recovery room. Hypothesis: Adding an intraoperative dose of intravenous acetaminophen to usual and customary analgesics during ambulatory surgery increases the proportion of patients remaining opioid-free in the post-anesthesia recovery room. Secondary Specific Aim: To determine if adding an intraoperative dose of intravenous acetaminophen to usual and customary analgesics during amublatory surgery impacts the required doses of additional perioperative analgesics. Hypothesis: Adding an intraoperative dose of intravenous acetaminophen to usual and customary analgesics during ambulatory surgery decreases the required doses of additional analgesics in both the operating room and post-anesthesia recovery room.

Registry
clinicaltrials.gov
Start Date
November 1, 2010
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Brian M. Ilfeld, MD, MS

Associate Professor, In Residence

University of California, San Diego

Eligibility Criteria

Inclusion Criteria

  • Undergoing ambulatory surgery under general anesthesia
  • Expected postoperative pain to be mild-moderate
  • Age 18 years or older
  • Have an ASA physical status or 1, 2, or 3

Exclusion Criteria

  • Anticipated peripheral or neuraxial nerve block
  • Any physical, mental or medical conditions which may confound quantifying postoperative pain resulting from surgery
  • Current chronic opioid or tramadol use
  • History of alcohol or opioid abuse
  • Known allergy to the study medications
  • Pregnancy
  • Any health condition requiring greater than 100 micrograms of fentanyl during anesthesia induction
  • Treated with any acetaminophen-containing medication in the previous 8 hours
  • Treated with MAO inhibitors within 10 days prior to surgery
  • Inability to communicate with the investigators and hospital staff

Arms & Interventions

IV Acetaminophen

Intraoperative IV acetaminophen administered

Intervention: Intravenous acetaminophen

IV Placebo

Intraoperative IV normal saline administered

Intervention: Intravenous placebo

Outcomes

Primary Outcomes

The primary endpoint is the difference in proportions of patients from each treatment group who avoid using any opioids following anesthesia emergence until recovery room discharge.

Time Frame: Day of Surgery

Secondary Outcomes

  • A secondary endpoint for this investigation will be the total dose of fentanyl administered to the patient.(Day of Surgery)
  • A secondary outcome for this investigation will be the total dose of morphine administered to the patient.(Day of Surgery)
  • A secondary outcome for this investigation will be the total dose of ibuprophen administered to the patient.(Day of Surgery)
  • A secondary outcome measure for this investigation will be the total dose of oxycodone administered to the patient.(Day of Surgery)
  • A secondary outcome measure will be any surgeon-administered local anesthetics used for wound infiltration.(Day of Surgery)
  • A secondary outcome measure for this study will be any recovery-room anti-emetics administered to the patient.(Day of Surgery)
  • Patients will be asked at time of PACU discharge, "Overall, how would you rate the study treatments?" Responses will be on 0 to 3 scale where 0=poor and 3=excellent.(Day of Surgery)
  • Patients will be asked at time of PACU discharge, "Overall, how would you rate the level of pain relief from study medication?" Responses will be on 0 to 3 scale where 0=poor and 3=excellent.(Day of Surgery)
  • Adverse events(Up to one year postoperative)

Study Sites (1)

Loading locations...

Similar Trials